Utomo, Sergey R Konstantinov, Marco J Bruno and Maikel P Peplenbosch. PCF fluid kindly 22 provided by Gastroenterologists Henri Braat, J.W. Poley, A.D. Koch. FFPE blocks kindly provided 23 by M. Doukas (Michael) pathology department, FFPE section were prepared by Juan Li 24 Gastroentrolgy & Hepatology department, training and help in confocal microscopy provided by Abstract 6 The involvement of bacterial translocation (BT) in the promotion of carcinogenesis has gained a 7 considerable attention in the last years. At this point however BT has not been studied in the 8 context of pancreatic cystic lesions and their development into pancreatic ductal adenocarcinoma. 9 The aim of the study was to analyze if bacteria are present in pancreatic cyst fluid (PCF) collected 10 from patients with suspected pancreatic cysts . Total DNA was isolated from sixty nine PCF. The 11 occurrence of bacteria in PCF was analyzed using bacterial 16S rRNA gene-specific PCR-based 12 method followed by sequence identification and quantitative PCR assay tuned up to different 13 pathogenic and commensal human bacteria. Forty-seven out of sixty-nine samples (68%) were 14 found positive for harboring bacterial 16S rRNA gene. Follow up sequencing analyses of the PCR 15 products revealed that bacterial species related to Fusobacterium spp., Bacteroides spp., and 16 Bacillus spp. were predominating the PCF samples. The results suggest that specific bacteria can 17 translocate to the pancreas and become detectable in the PCF. 18 19 20 21 22 23 24 25 26
Introduction 1
The incidence of pancreatic cystic lesions (PCL) in the general population is 2.4 percent. 2 Neoplastic pancreatic cysts represent a risk for developing pancreatic ductal adenocarcinoma 1 3 (PDAC) and account for up to 5% of the total incidence of pancreatic cancerous lesions 2,3 . The 4 clinical challenge in PCL is to identify signs of progressive neoplastic transformation in order to 5 perform a surgical resection before a malignancy develops. 6 The vast majority of cysts nowadays are asymptomatic and coincidental finding at cross sectional 7 imaging done for other reasons than cyst related symptoms.The percentage of cystic lesions being 8 resected is increasing with the clinical intention of preventing the development of PDAC. Different 9 types of cystic lesions are presently characterized by Grutzmann et. al., and Farrell et. al., which 10 include the intra-ductal papillary mucinous neoplasm (IPMNs), mucinous cystic neoplasms 11 (MCN), serous cyst adenomas (SCA), and pseudocysts 4,5 . IPMN's and MCN's pose a risk of 12 developing into carcinoma of which IPMNs are being more prevalent compared with MCN's 2,6 . 13 IPMNs are further classified as main branch, side branch or mixed types, based on the extent of 14 involvement of the pancreatic ductal system 5 . Presently, there are no validated biomarkers to 15 identify cystic lesions that require surgical resection. Although only up to three percent of the PCL 16 patients would develop cystic lesions to malignancy, ten percent of the PCL patients are resected 17 5 suggesting the need for more superior clinical tests and better patients' stratification prior to 18 surgery. 19 Currently, the decision for resection of PCL and/or continued monitoring are made 20 according to the Sendai guidelines after evaluation of different clinical tests 7-9 . The available 21 clinical tests include different biochemical analysis, cytology, pathological identification, 22 endoscopic ultra sonography (EUS), and radiological diagnosis such as endoscopic retrograde 23 cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP) and 24 whole body computerized tomography (CT). The inter-observer agreement, however, within and 25 between different modalities remains moderate. Therefore, a set of preoperative biochemical 26 analyses have been increasingly used in clinical decision making. This includes the study of cyst 27 fluids and serum for the characteristic presence of carcinoembryonic antigen (CEA), cancer 28 antigen 19.9 (CA-19.9), tumour associated glycoprotein 72-4 (CA-72-4), cancer antigen 15-3 (CA-29 15-3), pancreatic amylase, mucin antigens and along with cysts characteristics 10,11 . Other PCL 30 tests are based on specific analyses of different genetic modalities like K-RAS mutation and 1 miRNA, but are still under investigation awaiting further clinical validation 2,6,12,13 . Though 2 different diagnostic tests could help in decision making, none of them is sensitive and specific 3 enough to make the right decisions for all patients involved. Additional markers are therefore are 4 urgently needed to improve the management of PCL.
5
The human gut microbiome has emerged recently as an important environmental factor 6 linked to the development of different intestinal and extra-intestinal malignancies [14] [15] [16] . Several 7 members of the intestinal microbiome have been implicated in the bacterial translocation (BT) that 8 could occur during different diseases of the pancreas 17-21 . Numerous studies suggest that BT takes 9 place via the mesenteric lymph nodes route, followed by hepatic portal route, and trans mural or 10 biliary or duodenopancreatic reflux 18 . This may initiate and/or accelerates intestinal leakage with 11 a subsequent lowering of host immune response followed by dissemination of commensal gut 12 microbiota and their by-products to other organs leading to sepsis and major multiple organ 13 failures 21, 22 . BT has been demonstrated in induced acute pancreatitis in mice and other animal 14 models where BT takes place immediately towards the pancreatic duct causing necrosis in the 15 exocrine system of pancreas 19, 23 . Most of the BT has been described to originate from the small 16 intestine rather than from the colon 19 . BT-associated intestinal pathobionts include different 17 strains belonging to Escherichia coli, Enterobacter cloacae, Enterobacter fecalis, Proteus 18 mirabilis, and Pseudomonas species that have been involved in the necrotizing and acute 19 pancreatitis 18 . Although there is ample evidence that BT takes place in various pancreatic diseases, 20 not much has been studied nor understood about the bacterial presence in pancreatic cyst and/or 21 cyst fluids. In this discovery phase study we have attempted to establish the bacterial occurrence 22 in the pancreatic cystic lesions. The CT values in X axis were plotted against the serially diluted standards in Y axis to find 16 the intercept Y using the exponential trend line for the CT values as per the excel formula. The R 2 17 is also determined for the same plot. The Y intercept is used to calculate the ng of 16S rRNA for 18 the unknown samples of Fusobacterium spp., Bacteroides spp., Anaerococcus spp., 19 Acinitobacteria spp., Propionibacterium spp., and Staphylococcus spp.. Once the ng for each 20 sample is obtained they are used for calculating absolute copy number of 16s rRNA using the 21 following formula,
22
(SX1*6.02 x 10 14 ) + PX1*6.02 x 10 14 ) 23 16S rRNA copy number = 24 3.37 x 10 2 *Q1 25 Where in SX1 and PX1 -Sstands for supernatant, Pstands for the pellet, X1stands for the 26 sample 1, 6.02 x 10 14nano gram to Daltons, 3.37 x 10 2 molecular weight of one nucleotide in (Table 6 ). This confirms the bacterial DNA present in the PCF's. Table 4 . Based on the copy number the 16S rRNA were ranked the bacteria as 21 represented in Table 5 , which shows the pseudocysts (5.07 x 10 8 ) shows the highest copy number 22 for bacteria and the lowest also seen in SCA (3.53 x 10 5 ), corroborating the presence of bacteria 23 in pseudocysts as seen in earlier reports. The average bacterial 16S rRNA copy number /ml of PCF 24 was 1.08 x 10 7 with most occurring in pseudocysts (5.71 x 10 7 ) followed with MCN (1.15 x 10 7 ), 25 IPMN (2.04 x 10 6 ) others (GIST, NET and clinically undefined -1.92 x 10 6 ), and SCA (7.91 x 26 10 5 ) (Figure 1 ). One sample in pseudocysts, showed an abnormal bacterial load of 5.07 x 10 8 27 compared to other samples (Table 4) . Similarly, there are change in the number of 16S rRNA copy 28 number between various grades of dysplasia (graded according to the most atypical area in the 29 lesion) in IPMN in the decreasing order: 2.46 x 10 6 in no dysplasia, low grade dysplasia have 1.75 30 x 10 6 , Moderate dysplasia 9.67 x 10 5 and carcinoma in situ 8.30 x 10 5 (Fig 2, no statistical 1 difference). qPCR on PCF with mucinous cystic neoplasms have also demonstrated a higher 2 number of bacterial 16S rRNA gene in the samples where no dysplasia is present (Fig 3) . presence of other bacteria was also noted which included Ruminococcus spp., Staphylococcus spp., 14 Caldimonas spp., Arthrobacter spp., Acinetobacter spp., Bacteroides spp., Orpinomyces spp. 15 Anaerococcus spp (combined data from Tables 3 and 6) . bacterial presence by two personal specialized in confocal microscopy. We have confirmed it by 19 the confocal imaging of the FISH slides for the bacterial presence Figure 4 . Importantly, our 20 control samples, negative for bacterial presence in the PCF's were also negative in the tissue slices 21 generated after resection (data not shown). On the opposite side, the tissue samples from patients 22 with PCF positive for bacterial DNA were also positive for bacterial presence in the tissue, the 23 cysts borders and the duct borders (Figure 4) . In the current study we have demonstrated that 68 percent of the PCF harbour different 27 types of bacteria. The possible BT into the pancreatic cysts involve also bacteria related to F. 28 nucleatum implicated in adenoma to carcinoma transformation in epithelial cells 26 . Although 29 1 bacterial DNA on our cultivation-independent bacteriological findings. Nonetheless EUS-FNA 2 limitations for bacterial analyses need to be discussed. Before sampling cyst fluid, the needle tip 3 is exposed to the content in the stomach or gut lumen before being punctured through the gut wall 4 into the pancreatic cyst. The presence of bacterial 16S rRNA in all the 69 samples taken for this 5 study, observed as in the qPCR is due to the above said reasons of EUS-FNA being an non-sterile 6 procedure and also due to the bacterial products transferred via the other contaminants of the cyst 7 fluids, like blood which is plausibly carrying the bacteria DNA via the bacteria ingested 8 macrophages and other immune cells. To nullify and further account for that when interpreting our 9 data, we have performed confocal imaging for bacteria confirming that the tissue samples resected 10 from patients with PCF positive for bacterial DNA were also positive for bacterial presence in the 11 tissue. Furthermore, many bacteria in the stomach like H. pylori and streptococci were not found 12 in our PCF analyses supporting the notion that specific bacterial community may be associated 13 with PCF. 14 BT involvement into the pancreatic abscess, necrosis, pancreatitis, and pancreatic cyst have 15 also been reported mainly in isolated case studies, but never in large cohort analyses 22,27-29 . 16 Numerous case studies identified BT to pancreas were caused by the commensal bacteria and can potentially help us to distinguish between various cyst types and the difference between the 1 various grades of dysplasia.
2 It may also help in understanding the mechanism, whether it is a epiphenomenon or direct effect 3 of how the presence of specific type of bacteria can potentiate the primary cystic lesions 4 progressing towards pancreatic cancer. Furthermore, the data also raise a question of whether the 5 bacterial population as seen in the pancreatic cyst fluid as well the cyst margins and duct margins 6 could be a possible commensals of the pancreatic duct rather than bacterial invasion/translocation.
7
A more comprehensive study is required for understanding this phenomenon. 
